Introduction {#sec1}
============

Breast radiation therapy (RT) is a curative component of treatment for many breast cancer presentations, albeit with limited locoregional benefit for certain patients and no survival implications for others (eg, ductal carcinoma in situ \[DCIS\]).[@bib1] In the setting of the COVID-19 pandemic, in which community infection represents a mortal risk, the anticipated benefit of breast RT in certain settings must be carefully weighed against infectious risk.

Although breast cancer represents the most common noncutaneous malignancy in the United States, limiting the overall use and duration of breast RT under conditions of extreme resource constraints is prudent and may significantly alleviate institutional burdens. Guidance from the US Centers for Disease Control and World Health Organization advise limiting the sorts of person-to-person interactions that are likely to occur in clinical spaces among patients and healthcare staff during prolonged daily-fractionation regimens. In addition, health care resources in many settings may need to be repurposed for pandemic management such that limiting utilization is of renewed importance. Therefore, abbreviated fractionation regimens with nascent feasibility literature, as presented here, should be more strongly considered than under typical conservative practice conditions.

Methods and Materials {#sec2}
=====================

A team of radiation oncologists who specialize in breast cancer management at our comprehensive cancer center convened multidisciplinary and cross-institutional contingency planning meetings over the early days of the COVID-19 pandemic to review the relevant literature and establish recommendations for the safe application of hypofractionated and abbreviated radiation regimens. The literature was reviewed with an emphasis on randomized controlled trial and level 1 evidence, followed by prospective observational studies, systematic reviews, and meta-analyses (summary outlined in [Table 1](#tbl1){ref-type="table"}).

Suggested Considerations {#sec3}
========================

Omission of RT {#sec3.1}
--------------

In general, the omission of RT among those who are eligible should be prioritized. These subgroups of low-risk patients have been studied in landmark trials demonstrating a moderate local control benefit of RT without improvement in already excellent disease-specific survival outcomes.•*DCIS:* Prospective observational studies[@bib2] and randomized controlled trials[@bib3] have reproducibly demonstrated a lack of survival benefit for RT among favorable DCIS presentations. It is therefore advisable to forgo RT for those with mammographically detected lesions \<2.5 cm in size, of low or intermediate grade, and with adequate $\geq$2 mm resection margins.[@bib4] Caution is warranted if forgoing RT in patients under 40 years of age.[@bib5]^,^[@bib6]•*Invasive disease:* The omission of RT is preferred among those age 70 years and older who have estrogen-receptor positive (ER+) tumors that are $\leq$3 cm in size with no involved nodes (pT1-2N0M0), negative resection margins (ie, "no tumor on ink"[@bib7]), and who are eligible to receive endocrine therapy.[@bib8] A large study with limited follow-up suggested that lowering this threshold to 65 years of age is also safe.[@bib9] For patients younger than 65 years of age, ongoing studies demonstrate equipoise with regard to those who have biomarker-low disease that otherwise fits the previously mentioned clinicopathologic parameters, but no mature data exist in this domain.[@bib10], [@bib11], [@bib12]

Delaying RT {#sec3.2}
-----------

Uncertainty surrounding the current public health emergency has made predictions about future resource allocation particularly challenging. Estimates of population-level relief range from weeks to over 1 year.[@bib13]^,^[@bib14] In the interest of alleviating current workload and resource constraints, evidence exists to support delaying RT among certain populations, as follows:•*DCIS*: In patients requiring RT for DCIS, radiation can be safely delayed up to 12 weeks after breast-conserving surgery.[@bib15]•*Invasive disease*: Patients with early-stage, node-negative, ER+ breast cancer can safely begin RT 8 to 12 weeks after breast-conserving surgery without compromising disease control or survival, with several large studies showing that a delay up to 20 weeks may be safe in an appropriate subset.[@bib16]^,^[@bib17] There is limited evidence to guide the interval from chemotherapy to RT, and most trials initiate RT 4 to 6 weeks after chemotherapy. Extrapolation from the aforementioned surgical literature suggests that an interval of up to 12 weeks from chemotherapy to RT may be reasonable.

For patients with ER+ breast cancers, either DCIS or invasive, who may otherwise experience a delay or interruption in treatment, we support the prompt initiation of hormone therapy among those eligible. There is no evidence to suggest inferior local control or survival with concurrent hormonal therapy and radiation, including both tamoxifen[@bib18]^,^[@bib19] and aromatase inhibitors.[@bib20] Though subtle differences in breast edema, fibrosis/cosmesis, and lung toxicity have been reported, the overall evidence is mixed and should not limit use of concurrent therapy.[@bib21]

Accelerated partial breast irradiation {#sec3.3}
--------------------------------------

A large body of literature, including several landmark prospective trials, has established the safety and efficacy of accelerated partial breast irradiation (APBI) among appropriately selected patients. This paradigm is based on the historical observation that most recurrences occur proximate to the tumor cavity, such that treatment of the tumor bed with a margin has now been shown to confer outcomes similar to whole-breast RT in select settings. Moreover, utilization of a smaller target volume allows for acceleration of the overall regimen from 3 to 6 weeks to 1 to 2 weeks---a critical gain under resource-constrained circumstances. Additional benefits may include reduced acute toxicity, as evidenced by 10-year follow-up of the Florence regimen (30 Gy in 5 fractions, administered every other day).[@bib22]

Various techniques and fractionation regimens are available for partial breast radiation. The use of brachytherapy is discouraged in the setting of strain on hospital resources; it also yields increased opportunities for exposure and infection. Accelerated external beam partial breast radiation regimens using 3D conformal radiation therapy (3D-CRT) now have a large body of evidence supporting their use, with 38.5 Gy in 10 fractions delivered twice daily as a well-studied scheme. In one report, cosmesis appeared to score worse with this regimen,[@bib23] although in the seminal US study this appeared to be less of a concern.[@bib24] Other well-established options for APBI include 40 Gy in 10 fractions daily using 3D-CRT[@bib25]^,^[@bib26] and 30 Gy in 5 fractions every other day using intensity modulated radiation therapy[@bib22] (daily fractionation appears well tolerated; personal correspondence, March, 2020). Meanwhile, 40 Gy in 15 daily fractions to the partial breast is also an effective regimen, though it is more prolonged than the other APBI options.[@bib27]

American Society for Radiation Oncology (ASTRO) consensus guidelines[@bib28] and a group in the United Kingdom[@bib29] have identified a population for which there is reasonable agreement regarding suitability of APBI: patients 50 years of age or older with screen-detected invasive disease that is $\leq$2 cm in size, ER+, and node negative, or DCIS that is low/intermediate grade and $\leq$2.5 cm in size. Of note, NSABP-B39 also included 800 patients with ER-- breast cancer who exhibited excellent local control, suggesting that APBI may be reasonable among this group.

Whole-breast RT and hypofractionated regimens {#sec3.4}
---------------------------------------------

Among patients who require whole-breast RT without nodal treatment, hypofractionation is the preferred standard of care in the United States.[@bib30]^,^[@bib31] To that end, a number of fractionation schemes are well supported by randomized trials, including 42.56 Gy in 16 fractions[@bib32] and 40 Gy in 15 fractions.[@bib33] Data are emerging for more extreme hypofractionation, supporting 28.5 Gy in 5 once-weekly fractions,[@bib34] as well as a more accelerated daily regimen of 26 Gy in 5 daily fractions.[@bib35] Although long-term local recurrence data are not yet available for FAST FORWARD, 3-year normal tissue toxicity appears equivalent to the well-tolerated 3-week fractionation scheme. Although various concerns have slowed widespread adoption of shorter regimens for whole-breast radiation, a number of prospective phase 2, single-arm, and retrospective series have demonstrated efficacy and safety among groups that were previously thought to be of particular concern, including those with high-grade tumors,[@bib36] DCIS,[@bib37] young age,[@bib38] or triple-negative breast cancer.[@bib36]

Postmastectomy and/or regional nodal irradiation {#sec3.5}
------------------------------------------------

Analyses of 2 landmark studies, MA.20 and EORTC 22922, reproducibly demonstrated that regional nodal irradiation reduces distant recurrence risk and significantly improves disease-free survival, even among those with a limited axillary disease burden.[@bib39]^,^[@bib40] As a result, an increasing number of patients have become eligible to receive comprehensive regional nodal irradiation after breast conservation or PMRT. Unfortunately, hypofractionated nodal irradiation has yet to see widespread adoption in the United States, although a nascent literature does suggest it is safe to employ 40 Gy in 15 daily fractions targeting the breast/chest wall and regional nodes (presuming the supraclavicular hotspot is below 105%; otherwise, 39 Gy in 15 fractions is preferred),[@bib33]^,^[@bib41], [@bib42], [@bib43] with ongoing studies using this regimen in a randomized fashion to suggest true clinical equipoise (RT-CHARM: NCT03414970; FABREC: NCT03422103). The UK FAST FORWARD trial includes a 5-fraction lymphatic RT cohort, but this is not yet considered safe outside of a trial or in the setting of palliation.

Boost to the tumor bed {#sec3.6}
----------------------

Boost RT has more limited applications in emergency settings:•*DCIS*: The largest study to date evaluating the benefit of a boost in the setting of DCIS found a \<2% local control benefit following whole breast radiation.[@bib44] Given the absence of a survival benefit, boost can be omitted in resource-constrained settings, as was standard on Radiation Therapy Oncology Group (RTOG) 9804.[@bib3] However, as noted earlier, caution is warranted among those younger than 40 years of age, in whom boost was shown to improve local control by 10% at 72 months.[@bib45]•*Invasive disease:* Following whole breast radiation, a tumor bed boost should be considered only in the presence of significant local recurrence risk factors: ≤60 years of age, high grade tumors, or inadequate margins.[@bib46]

A standard boost after hypofractionated whole breast radiation involves 4 to 6 fractions, although evidence suggests that a simultaneous integrated boost may be similarly safe and effective.[@bib47]^,^[@bib48] In the setting of ultrahypofractionation with 5-fraction regimens, it is reasonable to consider a single 5.2 Gy dose to the tumor bed (personal correspondence), although this fractional boost dose remains to be reported beyond the brachytherapy literature.[@bib49]

For patients receiving whole breast and nodal irradiation, a simultaneous integrated boost (SIB) can reduce treatment visits. This can be achieved with intensity modulated radiation therapy or volumetric modulated arc therapy but is also possible with a supplemental electron field delivered with each 3D-CRT fraction.

Patient prioritization {#sec3.7}
----------------------

Under extreme circumstances, it may be necessary to prioritize which patients with breast cancer can receive RT services. Prioritization of patients for whom RT is anticipated to provide a survival benefit is paramount. Based on available evidence and nascent clinical judgement, we have defined tiers of elevated priority ([Table 2](#tbl2){ref-type="table"}). Of note, prioritization within each tier is left to the treating physician's discretion based on patient age, comorbidities, risk of exposure, and predicted benefit of RT.Table 1Hypofractionated or accelerated breast radiation therapy regimensTargetTotal dose/no. of fractionsTechnique/contoursDose constraints (for shortest regimen only)NotesPartial breast30 Gy/5 every other day (preferred) or daily (acceptable)\
40 Gy/10 dailyIMRT/VMAT (preferred)\
3D-CRT\
GTV (clips∗) to PTV \~2 cm (1.5 cm to CTV with 5 mm PTV margin)[30 Gy in 5 fractions:]{.ul}\
D~max~ \<110%\
V105%(31.5 Gy) \<5% of breast volume\
Ipsi breast-PTV V15Gy \<50%\
Contra breast D~max~ \<1Gy\
Lung (ipsi) V10Gy \<20%\
Lung (contra) V5Gy \<10%Florence PBI trial[@bib22]\
<http://econtour.org/cases/47>\
MSK prospective[@bib25]^,^[@bib26]\
<http://econtour.org/cases/108>∗Clips strongly preferred for targeting and daily setup∗Daily kv match to clips vs CBCT match to seromaWhole breast26 Gy/5 daily ± 5.2 Gy × 1 boost\
40 Gy/15 daily\
42.4 Gy/16 daily3D-CRT\
For left-sided, DIBH (preferred) and/or heart block[26 Gy in 5 fractions:]{.ul}\
D~max~ \<110%\
V107% \<2% of breast volume\
V105% \<5% of breast volume\
Lung V8Gy \<15% (\<17% acceptable)\
Heart V7Gy \<5%, V1.5Gy \<30%UK FAST FORWARD[@bib35]\
<http://econtour.org/cases/117>Postmastectomy (PMRT)42.56 Gy/163D-CRT or IMRT[42.56 Gy in 16 fractions:]{.ul}\
D~max~ \<115%\
V107% \<10 cm^3^ of PTV\
Contra breast V3Gy \<10% (preferred), V5Gy \<10% (acceptable)\
Lung V18Gy ≤35% (≤40% acceptable)\
Heart mean ≤3 Gy (preferred),\
≤5 Gy (acceptable)\
Heart V22.5Gy \<10% (left-sided),\
V22.5Gy \<2% (right-sided)RTCHARM (NCT03414970)\
<http://econtour.org/cases/110>Breast and RNI42.56 Gy/16 with SIB to tumor bed 48 Gy/16 (3 Gy/fx)\
40 Gy/15 with SIB^†^ to tumor bed 48 Gy/15 (3.2 Gy/fx)3D-CRT or IMRT\
3D CRT SIB involves a separate electron plan delivered after photon plan\
Seroma/clips 7-10 mm for CTV, then another 5-7 mm for PTV. NOTE: expansions can be smaller for SIB.(see PMRT constraints)UK START B[@bib33] and extrapolation from RTOG 1005[@bib50]^†^SIB: EQD2 57Gy for a/b 3[^2][^3]Table 2Prioritization of radiation for breast cancer based on treatment indicationTier 1\
(high priority for breast RT)•Inflammatory breast cancer•Residual node positivity after NAC•4 or more positive nodes (N2)•Recurrent disease•Node-positive TNBC•Extensive LVITier 2\
(intermediate priority for breast RT)•ER+ with 1-3 positive nodes (N1a)•Path N0 after NAC•LVI (NOS)•Node negative TNBCTier 3\
(low priority for breast RT)•Early-stage ER+ breast cancer (esp. older)•DCIS•Otherwise not meeting criteria for tiers 1-2[^4]

Discussion {#sec4}
==========

As governments restrict public movement to limit continued spread of the SARS-CoV-2 pandemic, radiation oncologists must now make an unprecedented calculus on behalf of our patients: the mortal risk of presenting for treatment and being exposed to infection versus the benefit of RT itself. It therefore behooves us to consider (1) omitting RT when appropriate, (2) delaying radiation while initiating hormone therapy in low-risk patients with ER+ breast cancer, and (3) rapidly adopting accelerated schemes when possible in a concerted effort to protect our communities and conserve scarce health care resources.

For illustrative case presentations and guidance in contouring and planning the various regimens described, including target volumes, organs at risk, and relevant expansions, please visit <http://econtour.org/hypofrac>. Online cases also include dosimetric guidance and the dose constraints used in various supportive protocols.
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[^3]: For illustrative case presentations and guidance in contouring and planning the various regimens described, including target volumes, organs at risk, and relevant expansions, please visit <http://econtour.org/hypofrac>. Online cases also include dosimetric guidance and the dose constraints used in various supportive protocols.

[^4]: *Abbreviations*: DCIS = ductal carcinoma in situ; ER+ = estrogen-receptor positive; LVI = lymphovascular invasion; NAC = neoadjuvant chemotherapy; NOS = not otherwise specified; RT = radiation therapy; TNBC = triple negative breast cancer.
